Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New book on supplement industry

This article was originally published in The Tan Sheet

Executive Summary

"Natural Causes: Death, Lies and Politics in America's Vitamin and Herbal Supplement Industry," a book Random House bills as "a riveting work of investigative journalism that charts the rise of the dietary supplement craze and reveals the dangerous - and sometimes deadly - side of these highly popular and completely unregulated products," is slated for release Dec 26. The publishing company says author Dan Hurley, a contributing journalist to the New York Times, "charts the remarkable growth of an industry built largely on fraud, and reveals the backroom politics that led to the passage of the Dietary Supplement Health & Education Act of 1994, which effectively freed the industry from FDA oversight," the publisher continues. "In unprecedented detail, he shows how supplement manufacturers have concealed the truth about dozens of untested treatments and the shocking rise in deaths, disfigurements, and life-threatening injuries cause by products deceptively promoted as 'safe and natural'"...

You may also be interested in...



Strong Presence On The Hill Needed Now, Not When Hearings Start - Panelists

Rep. Henry Waxman, D-Calif., will hold hearings on dietary supplements, lobbyists Jack Martin and Ed Long confirmed. "The question ... is are you going to get active the day you get your subpoena or do you want to start getting active right now.

With US Respiratory Pipeline Unlocked, Cipla Wants Lung Leadership

Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.

Teva CEO Schultz: ‘Proof Is In The Pudding’ For US Biosimilars

Teva CEO Kåre Schultz believes his prediction is coming true for the Truxima biosimilar in-licensed from Celltrion, as he gave the latest update on Teva’s efforts to settle significant legal issues around the US opioid crisis.

Topics

UsernamePublicRestriction

Register

ID1132298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel